Last reviewed · How we verify
AGI-1067
At a glance
| Generic name | AGI-1067 |
|---|---|
| Also known as | AGI-1067 (succinobucol) |
| Sponsor | AtheroGenics |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study (PHASE2, PHASE3)
- ARISE - Aggressive Reduction of Inflammation Stops Events (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGI-1067 CI brief — competitive landscape report
- AGI-1067 updates RSS · CI watch RSS
- AtheroGenics portfolio CI